Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sanofi-Aventis extends Zentiva's offer into February

This article was originally published in Scrip

Executive Summary

Sanofi-Aventishas received permission to postpone the expiry date for the validity of its offer to acquire Zentivafrom November 28th to February 20th, 2009. Sanofi-Aventis Europe offered to buy all of Zentiva's shares, including GDSs, for CK1,150 ($59.30) per sharethis summer (Scrip Online, June 23rd, 2008). The content of its offer allowed Sanofi-Aventis Europe to extend the validity period at the Czech National Bank's consent, if additional time is needed to meet all the conditions. The company requested the extension because it failed to obtain positive opinions from all the competition authorities by the end of November. It has received them from the competition authorities of Russia, Ukraine and Turkey, but not yet the European Union, Sanofi-Aventis said.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts